

PHARMACY TIMES

BY IEHP PHARMACEUTICAL SERVICES DEPARTMENT April 4, 2022

COVID-19: Test to Treat

Dear IEHP Providers,

The Biden-Harris Administration launched a new nationwide <u>COVID-19 Test to Treat</u>
Initiative to give individuals a way to quickly access free lifesaving treatment for COVID-19.
These "One-Stop Test to Treat" sites include pharmacy-based clinics, Health Resources Services Administration (HRSA)-supported Federally Qualified Health Centers (FQHCs), and long-term care facilities.

At these locations, Members are able to get tested and – if they are positive and treatments are appropriate for them – receive a prescription from a health care provider and their prescription filled. Sites participating in the initiative receives the COVID-19 oral antiviral pills from Merck's LAGEVRIO (MOLNUPIRAVIR) and Pfizer's PAXLOVID (NIRMATRELVIR / RITONAVIR).

Members can continue to be tested and treated by their own health care providers who can appropriately prescribe these oral antivirals at locations where the medicines are distributed. Testing sites can be located for our members who need urgent access to the drugs through the link provided below.

Test to Treat Locator: https://covid-19-test-to-treat-locator-dhhs.hub.arcgis.com/

For more information about COVID-19 Test to Treat, please visit:

https://aspr.hhs.gov/TestToTreat/Documents/Fact-Sheet.pdf

As a reminder, all communications sent by IEHP can also be found on our Provider portal at: www.iehp.org > For Providers > Plan Updates > Correspondence

If you have any questions, please do not hesitate to contact the IEHP Provider Relations Team at (909) 890-2054 or (866) 223-4347.